Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Enhancing HCP Education in Adult Vaccination against Respiratory InfectionsRelease Date:Education Vaccines Austria, Belgium, Greece, Ireland, Luxembourg, Portugal, Switzerland Migraine and Women’s HealthQuality Improvement, Research Internal Medicine USA Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology All Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare ProfessionalsRelease Date:Education Rare Disease USA Prostate Cancer: Best Practices for Combining Targeted Therapies in mPCRelease Date:Education Oncology USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Research Rare Disease USA Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Title Grant Type Focus Area Country Application Due Date Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Fellowship Rare Disease USA Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple MyelomaRelease Date:Partner: National Comprehensive Cancer NetworkResearch Oncology USA PARP-inhibitor Combination Treatments in Prostate CancerRelease Date:Education Oncology USA Approaches to Increase Equitable Access to and Delivery of Quality of Care with BsAb for Patients with Mutiple MyelomaRelease Date:Partner: International Myeloma FoundationQuality Improvement Oncology All Improving the care and outcomes of Canadians living with metastatic NSCLCRelease Date:Partner: Lung Health Foundation, Lung Cancer Canada, Quebec Lung AssociationQuality Improvement Oncology Canada Committing to Support Elderly Cancer PatientsRelease Date:Partner: Japan Society of Clinical OncologyEducation Oncology Japan Establishing System for Early Detection of Atrial Fibrillation and Prevention of Cardioembolic StrokeRelease Date:Quality Improvement Internal Medicine Japan Improving Early Detection and Appropriate Anticoagulant Therapy for Atrial FibrillationRelease Date:Education Internal Medicine Japan Promoting Understanding of Maternal ImmunizationRelease Date:Education Vaccines Japan Promoting Understanding of Pneumonia PreventionRelease Date:Education Vaccines Japan Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid CardiomyopathyRelease Date:Education Rare Disease USA Treatment Environment of Appropriate antiviral therapy for COVID-19 InfectionsRelease Date:Education Hospital Japan